Referências

 

1 – Wikipédia Propofol : http://en.wikipedia.org/wiki/Propofol (acedido em 31.05.2015)

2 – Earley P., Finver T. (2013) Addiction to Propofol: A Study of 22 Treatment Cases, J Addict Med (2013);00: 1–8

3- KOOPMANN, A. GOLTZ,, C. HERMANN, C. KIEFER, F. (2011), Propofol Addiction Initiated by Anesthetic Use Am J Psychiatry 168:2

4 – Infomed Propofol: https://www.infarmed.pt/infomed/lista.php (acedido em 28.05.2015)

5 - HIGHLIGHTS OF PRESCRIBING INFORMATION: Propofol, FDA (acedido em 28.05.2015)

6- WHO Model Lists of Essential Medicines: http://www.who.int/medicines/publications/essentialmedicines/en/ (acedido em 28.05.2015)

7 - State by State Lethal Injection, Death Penalty Information Center: http://www.deathpenaltyinfo.org/state-lethal-injection (acedido em: 28.05.2014)

8 - Pramanik,C.; Kotharkar, C.; Patil, P.; Gotrane, D.; More, P. (2013) Commercial Manufacturing of Propofol: Simplifying the Isolation Process and Control on Related Substances, Org. Process Res. American Chemical Society  (2014), 18, 152−156

9 – Propofol – PubChem Open Chemistry Database: https://pubchem.ncbi.nlm.nih.gov/compound/4943#section=Chemical-and-Physical-Properties (acedido em: 26.05.2015)

 

10 – Resumo das características do medicamento – Propofol; Infarmed : http://www.infarmed.pt/infomed/download_ficheiro.php?med_id=2692&tipo_doc=rcm (acedido em 22.05.2015)

11 -  Birk J1, Bath RK.(2015)  Is the anesthesiologist necessary in the endoscopy suite? A review of patients, payers and safety, Expert Rev Gastroenterol Hepatol. 2015 May 15:1-3.

12 - Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 345

13 - USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002.., p. 2466

14 - Ellenhorn, M.J., S. Schonwald, G. Ordog, J. Wasserberger. Ellenhorn's. Medical Toxicology: Diagnosis and Treatment of Human Poisoning. 2nd ed. Baltimore, MD: Williams and Wilkins, 1997., p. 1181

15 - Y.Kotani,M.Shimazawa,S.Yoshimura,T.Iwama,andH.Hara, The experimental and clinical pharmacology of propofol, an anesthetic agent with neuroprotective properties,CNS Neuro- science and Therapeutics, vol. 14, no. 2, pp. 95–106, 2008

16 Franks NP: Molecular targets underlying general anaesthesia. Br J Pharmacol. 2006 Jan;147 Suppl 1:S72-81

17 Haeseler G, Karst M, Foadi N, Gudehus S, Roeder A, Hecker H, Dengler R, Leuwer M: High-affinity blockade of voltage-operated skeletal muscle and neuronal sodium channels by halogenated propofol analogues. Br J Pharmacol. 2008 Sep;155(2):265-75. Epub 2008 Jun 23. 

18 Y.Kotani,M.Shimazawa,S.Yoshimura,T.Iwama,andH.Hara, “The experimental and clinical pharmacology of propofol, an anesthetic agent with neuroprotective properties,” CNS Neuro- science and Therapeutics, vol. 14, no. 2, pp. 95–106, 2008

19 http://www.drugbank.ca/drugs/DB00818#pharmacology, consultado em 19 de maio de 2015.

20 http://www.anesthesiawiki.net/metrohealthanesthesia/MHAnes/images/propofolMetab.jpg, acedido em 19 de maio de 2015

21 – Propofol – Drug bank : http://www.drugbank.ca/drugs/DB00818#interactions (acedido em 19.05.2015)

22 - Medical Economics Co; Physicians Desk Reference 56th ed p. 667 (2002)

22 - Mirrakhimov, Aibek E., et al. "Propofol Infusion Syndrome in Adults: A Clinical Update." Critical care research and practice 2015 (2015).

23 - T.G.ShortandY.Young,“Toxicityofintravenousanaesthetics,” Best Practice and Research: Clinical Anaesthesiology, vol. 17, no. 1, pp. 77–89, 2003.

23 - X. Jouven, M.-A. Charles, M. Desnos, and P. Ducimetie`re, “Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population,” Circulation, vol. 104, no. 7, pp. 756–761, 2001.

24 - L. W. Andersen, J. Mackenhauer, J. C. Roberts, K. M. Berg, M. N. Cocchi, and M. W. Donnino, “Etiology and therapeutic approach to elevated lactate levels,” Mayo Clinic Proceedings, vol. 88, no. 10, pp. 1127–1140, 2013.

25 - T. J. Schroeppel, T. C. Fabian, L. P. Clement et al., “Propofol infusion syndrome: a lethal condition in critically injured patients eliminated by a simple screening protocol,” Injury, vol. 45, no. 1, pp. 245–249, 2014

27 . S. M. Forsythe and G. A. Schmidt, “Sodium bicarbonate for the treatment of lactic acidosis,” Chest, vol. 117, no. 1, pp. 260–267, 2000.

28 . J.-S. Rachoin, L. S. Weisberg, and C. B. McFadden, “Treatment of lactic acidosis: appropriate confusion,” Journal of Hospital Medicine, vol. 5, no. 4, pp. E1–E7, 2010.

29 . H. A. Cooper and J. A. Panza, “Cardiogenic shock,” Cardiology Clinics, vol. 31, no. 4, pp. 567–580, 2013.

30 . M. Khan, B. Corbett, and S. Hollenberg, “Mechanical circula- tory support in acute cardiogenic shock,” F1000Prime Reports, vol. 6, article 91, 2014.

31 . W. Zhou, H. J. Fontenot, S.-N. Wang, and R. H. Kennedy, “Propofol-induced alterations in myocardial beta-adrenoceptor binding and responsiveness,” Anesthesia and Analgesia, vol. 89, no. 3, pp. 604–608, 1999.

32. W.Zhou,H.J.Fontenot,S.Liu,andR.H.Kennedy,“Modulation of cardiac calcium channels by propofol,” Anesthesiology, vol. 86, no. 3, pp. 670–675, 1997.

33  M. Mayette, J. Gonda, J. L. Hsu, and F. G. Mihm, “Propofol infu- sion syndrome resuscitation with extracorporeal life support: a case report and review of the literature,” Annals of Intensive Care, vol. 3, no. 1, pp. 1–6, 2013.

34 . A. Wolf, P. Weir, P. Segar, J. Stone, and J. Shield, “Impaired fatty acid oxidation in propofol infusion syndrome,” The Lancet, vol. 357, no. 9256, pp. 606–607, 2001.

35  K.Ahlen,C.J.Buckley,D.B.Goodale,andA.H.Pulsford,“The ‘propofol infusion syndrome’: the facts, their interpretation and implications for patient care,” European Journal of Anaesthesiol- ogy, vol. 23, no. 12, pp. 990–998, 2006.

36. M. S. Roth, A. B. Martin, and J. A. Katz, “Nutritional implica- tions of prolonged propofol use,” American Journal of Health- System Pharmacy, vol. 54, no. 6, pp. 694–695, 1997.

37 - Sangseok L. Guilty, or not guilty?: a short story of propofol abuse Korean J Anesthesiol 2013 November 65(5): 377-378

38 - Wilson C, Canning P, Caravati EM: The abuse potential of propofol. Clin Toxicol (Phila). 2010; 48:165–170

39 - Anne R., Jean-Louis M., Maryse L . tPharmacologia and clinical evidences on the potencial for abuses and dependence of propofol: a review of the literature, Fundamental & Clinical Pharmacology 21 (2007) 459–465

40 - Bonnet, U. Scherbaum N., (2012) Craving Dominates Propofol Addiction of an Affected Physician Journal of Psychoactive Drugs, 44 (2), 186–190, 2012

41 - Earley, P. Finver (2013), P. Addiction to Propofol: A Study of 22 Treatment Cases, J Addict Med 2013;00: 1–8

42 -Ferreira, A, Borges, A., Rangel, R. Monsanto, P., Dias, M., Carvalho, M. Avaliação da intoxicações medicamentosas em Portugal, Centro de informação Antiveneno, 2008

43 – Propofol – Drug bank : http://www.drugbank.ca/drugs/DB00818#interactions (acedido em 19.05.2015)

44 - Medical Economics Co; Physicians Desk Reference 56th ed p. 667 (2002)

45 - Goldfrank LR et al, eds.; Goldfrank's Toxicologic Emergencies. 7th ed. p. 940 (2002)